Overview Layer-3 blockchains are emerging as the next evolution in scaling beyond Layer-2, offering custom environments for ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Erythritol, a widely used sugar substitute found in many low-carb and sugar-free products, may not be as harmless as once believed. New research from the University of Colorado Boulder reveals that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback